Gilead Sciences | GILD - Trade Creditors

Stock Price
129.13
Daily Change
1.38 1.08%
Monthly
-5.29%
Yearly
23.91%
Q2 Forecast
127.61

Gilead Sciences reported $715M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
ALKERMES USD 107.95M 39.95M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
Biogen USD 432M 18.9M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Gilead Sciences USD 715M 93M Dec/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Incyte USD 1.63B 1.46B Dec/2025
J&J USD 10.46B 1.53B Mar/2026
Merck USD 4.15B 102M Sep/2025
Moderna USD 317M 50M Dec/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Novartis USD 4.46B 99M Dec/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 280.84M 186.83M Dec/2025
United Therapeutics USD 7.1M 460.9M Dec/2025
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025